News
Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting
Cambridge, UK; June 1, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced a poster presentation detailing updates on the ongoing clinical trial of the company’s anti-ICOS program KY1044 at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The poster details the first-in-human clinical study (NCT03829501) of KY1044, Kymab’s fully human anti-ICOS IgG1 antibody. KY1044 is designed to both deplete intratumoral regulatory T cells and stimulate effector T cells to promote the immune response against tumors. The study was initiated in February of this year.